HUGE CALL OPTION ACTIVITY IN INTRA CELLULAR THERAPIES.

The company has a recent failed trial but has many more in the pipeline, this may be the catalysts for the increase in option trades in the past month. There has also been notable insider buying in May and the company has a strong balance sheet. We will be keeping a very close eye on the newsflow regarding trial updates.


AVERAGE ANALYSTS PRICE TARGET $28.90
AVERAGE ANALYSTS RECOMMENDATION BUY
SHORT INTEREST 9.6%


COMPANY PROFILE
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.